Abstract
IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broadspectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin) and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.
Keywords: inosine monophospate dehydrogenase, imp dehydrogenase, purine nucleotides, mycophenolic mofetil
Current Medicinal Chemistry
Title: Cofactor Mimics as Selective Inhibitors of NAD-dependent Inosine Monophospate Dehydrogenase (IMPDH) - the Major Therapeutic Target
Volume: 11 Issue: 7
Author(s): Krzysztof W. Pankiewicz, Steven E. Patterson, Paul L. Black, Hiremagalur N. Jayaram, Dipesh Risal, Barry M. Goldstein, Lieven J. Stuyver and Raymond F. Schinazi
Affiliation:
Keywords: inosine monophospate dehydrogenase, imp dehydrogenase, purine nucleotides, mycophenolic mofetil
Abstract: IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broadspectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin) and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.
Export Options
About this article
Cite this article as:
Pankiewicz W. Krzysztof, Patterson E. Steven, Black L. Paul, Jayaram N. Hiremagalur, Risal Dipesh, Goldstein M. Barry, Stuyver J. Lieven and Schinazi F. Raymond, Cofactor Mimics as Selective Inhibitors of NAD-dependent Inosine Monophospate Dehydrogenase (IMPDH) - the Major Therapeutic Target, Current Medicinal Chemistry 2004; 11 (7) . https://dx.doi.org/10.2174/0929867043455648
DOI https://dx.doi.org/10.2174/0929867043455648 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Preliminary COX-2 Expression Inhibitory Activities of Andrographolide Derivatives
Letters in Drug Design & Discovery The Role of Anticoagulation in Cancer Patients: Facts and Figures
Anti-Cancer Agents in Medicinal Chemistry Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Review: Precision Cut Liver Slices for the Evaluation of Fatty Liver and Fibrosis
Current Molecular Pharmacology Stimuli-responsive Drug Delivery Systems as an Emerging Platform for Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Editorial [Hot topic: Inflammation, Immunity, and Alzheimers Disease (Guest Editor: Terrence Town)]
CNS & Neurological Disorders - Drug Targets Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression
Current Medicinal Chemistry Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Current Topics in Medicinal Chemistry Piceatannol Modulates Lung Epithelial Cellular Responses to Pseudomonas aeruginosa
Inflammation & Allergy - Drug Targets (Discontinued) Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases
Current Drug Targets Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Current Molecular Medicine Administration of a Synbiotic to Free-Living Elderly and Evaluation of Serum Cytokines. A Pilot Study
Current Pharmaceutical Design Treatment Modalities for Hepatocellular Carcinoma
Current Cancer Drug Targets Psychiatric Side Effects of Interferon Treatment
Current Drug Safety Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Targeting the Endothelial Ca2+ Toolkit to Rescue Endothelial Dysfunction in Obesity Associated-Hypertension
Current Medicinal Chemistry TREM2 and the Progression of Alzheimer’s Disease
Current Neurovascular Research Interactions of Biologically Active Factors and Vascular Mediators During Hypertension in Pregnancy
Current Hypertension Reviews